Figure 4.

GYS2-1 Treatment Reduces Circulating Liver Enzymes in an Agl^−/− GSD III Mouse Model

GYS2-1 was subcutaneously injected into WT or Agl^−/− mice weekly at a 10 mg/kg dose starting at 4 or 8 weeks of age and sacrificed at 13 or 26 weeks of age, respectively, as indicated. Analysis of serum samples was performed to measure circulating liver enzymes. ALT, alanine transaminase; AST, aspartate aminotransferase; ALP, alkaline phosphatase. Data are presented as mean ± SD. Unpaired t test for statistical significance relative to PBS treatment group. WKS, weeks. ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05.